SLC1A4 and SLC38A2 (alanine transporter) [59] and SLC1A5 (ASCT2-glutamine transporter) [98] enhance PDAC tumor growth by importing essential amino acids and therefore represent additional potential therapeutic targets. Here, SLC1A5 is linked to neoplasm.